PG 36

Drug Profile

PG 36

Latest Information Update: 19 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmagenesis
  • Class Antineoplastics; Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cytomegalovirus infections
  • Discontinued Cancer; Viral hepatitis

Most Recent Events

  • 19 Oct 2015 Preclinical trials in Cytomegalovirus infections in USA (unspecified route) before October 2015
  • 18 Apr 1997 No-Development-Reported for Cancer in USA (unspecified route)
  • 18 Apr 1997 No-Development-Reported for Viral hepatitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top